Emerging research highlights the potential of melatonin, a hormone primarily known for regulating sleep, in cancer prevention and treatment. Studies indicate that lower urinary melatonin levels are associated with an increased risk of advanced prostate and breast cancers. Additionally, melatonin supplementation has been observed to enhance the effectiveness of certain cancer therapies and mitigate treatment-related side effects, such as low platelet counts and neurotoxicity.
Its antioxidant properties, immunomodulatory effects, and ability to regulate estrogen receptor expression further contribute to its oncostatic (cancer-inhibiting) functions. Click for More Details
